Login / Signup

Annual severity increment score as a tool for stratifying patients with Niemann-Pick disease type C and for recruitment to clinical trials.

Mario Cortina-BorjaDanielle Te VruchteEugen MengelYasmin AmraouiJackie ImrieSimon A JonesChristine I DaliPaul FineranThomas KirkegaardHeiko RunzRobin LachmannTatiana Bremova-ErtlMichael StruppFrances Mary Platt
Published in: Orphanet journal of rare diseases (2018)
ASIS has the potential to be a useful metric for clinical monitoring, trial recruitment, for prognosis and measuring response to therapy.
Keyphrases
  • clinical trial
  • phase ii
  • phase iii
  • study protocol
  • open label
  • randomized controlled trial
  • double blind
  • risk assessment
  • bone marrow
  • cell therapy